Markus Hecker

Director-Physiology & Pathophysiology at University of Heidelberg, Germany

Markus Hecker

Markus Hecker

Director-Physiology & Pathophysiology at University of Heidelberg, Germany

Overview
Career Highlights

Avontec GmbH

RelSci Relationships

114

Relationships
RelSci Relationships are individuals Markus Hecker likely has professional access to. A relationship does not necessarily indicate a personal connection.

General Partner, Life Sciences at Wellington Partners GmbH

Relationship likelihood: Strong

Chairman-Ophthalmology Department at University of Heidelberg, Germany

Relationship likelihood: Strong

Member, Board of Trustees at University of Heidelberg, Germany

Relationship likelihood: Strong

Vice President at Bundesvereinigung der Deutschen Arbeitgeberverbände BV

Relationship likelihood: Strong

Managing Partner at Freudenberg & Co. KG

Relationship likelihood: Strong

Former Chairman & Chief Executive Officer at Knoll AG

Relationship likelihood: Strong

Section Head of Endocrinology-5th Medical Department, University Medical Center Mannheim at University of Heidelberg, Germany

Relationship likelihood: Strong

President at Max Planck Foundation

Relationship likelihood: Strong

Vice President of Business Development & Marketing in Europe at EirGenix, Inc.

Relationship likelihood: Strong

Professor at University of Heidelberg, Germany

Relationship likelihood: Strong

Paths to Markus Hecker
Potential Connections via
Relationship Science
You
Markus Hecker
Director-Physiology & Pathophysiology at University of Heidelberg, Germany
Education

University of Konstanz provides top-class research, excellence in teaching and studies, inter-nationality and interdisciplinary cooperation.

Career History
Director-Physiology & Pathophysiology
Current

Ruprecht-Karls-Universität Heidelberg

Director-Supervisory Board & Co-Founder
2001 - 2010

Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease.Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology.Avontec operates based on a lean business model with a seasoned management team experienced in clinical development.

Professional
1996 - 2004

The University of Göttingen, known informally as Georgia Augusta, is a public comprehensive research university.

Investments
Details Hidden

Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease.Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology.Avontec operates based on a lean business model with a seasoned management team experienced in clinical development.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Markus Hecker. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Markus Hecker's profile does not indicate a business or promotional relationship of any kind between RelSci and Markus Hecker.